Aurinia to Start Phase 3 Trial of Lupus Nephritis Treatment, Voclosporin, in 2017
Aurinia Pharmaceuticals will take its drug candidate voclosporin into a possibly pivotal Phase 3 clinical trial of its efficacy in treating lupus nephritis — kidney disease caused by systemic lupus erythematosus. Following Phase 2 study meetings with the U.S. Food and Drug Administration (FDA), Aurinia believes the new trial will provide…